Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Lantheus (LNTH – Research Report). The associated price target remains the same with $120.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Justin Walsh has given his Buy rating due to a combination of factors that highlight Lantheus’s strategic positioning and growth potential in the radiopharmaceutical field. The company showcased its PYLARIFY and LNTH-1363S programs at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, emphasizing its strong presence in the market for PSMA-targeted PET imaging agents. Despite the competitive landscape, PYLARIFY is noted for its clinical preference over competitors like POSLUMA, and the company is praised for its effective commercial execution strategies.
Additionally, Lantheus is actively developing new opportunities in FAP-targeted PET imaging and neuroimaging, particularly in amyloid and Tau PET imaging, which are promising for medium- to long-term growth. The company’s ability to navigate the evolving reimbursement landscape and its solid financial position with substantial cash reserves further support the Buy rating. These factors collectively contribute to the confidence in Lantheus’s potential to maintain its market-leading position and achieve the set price target of $120.
Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Achieve Life Sciences, and Bioline RX Ltd Sponsored ADR. According to TipRanks, Walsh has an average return of -2.0% and a 33.06% success rate on recommended stocks.
In another report released on June 23, B.Riley Financial also maintained a Buy rating on the stock with a $109.00 price target.